FMO3 sirna

FMO3 siRNA (Human)

Cat. Num. AAA8222815

• Gene Names: FMO3; TMAU; FMOII; dJ127D3.1
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: FMO3; FMO3 siRNA (Human); Dimethylaniline monooxygenase [N-oxide-forming] 3; Dimethylaniline oxidase 3; FMO II; FMO form 2; Hepatic flavin-containing monooxygenase 3; FMO 3; Trimethylamine monooxygenase; FMO3 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: FMO3 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 532

• Applicable Applications for FMO3 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human FMO3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for FMO3 sirna

siRNA to inhibit FMO3 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 50541961
• NCBI GeneID: 2328
• NCBI Accession #: NP_001002294.1
• NCBI GenBank Nucleotide #: NM_001002294.2
• UniProt Accession #: P31513; Q14854; Q8N5N5; B2R816
• Molecular Weight: 60,033 Da
• NCBI Official Full Name: dimethylaniline monooxygenase
• NCBI Official Synonym Full Names: flavin containing monooxygenase 3
• NCBI Official Symbol: FMO3
• NCBI Official Synonym Symbols: TMAU; FMOII; dJ127D3.1
• NCBI Protein Information: dimethylaniline monooxygenase [N-oxide-forming] 3
• UniProt Protein Name: Dimethylaniline monooxygenase [N-oxide-forming] 3
• Protein Family: Dimethylaniline monooxygenase
• UniProt Gene Name: FMO3
• UniProt Synonym Gene Names: FMO 3
• UniProt Entry Name: FMO3_HUMAN

NCBI Description

Flavin-containing monooxygenases (FMO) are an important class of drug-metabolizing enzymes that catalyze the NADPH-dependent oxygenation of various nitrogen-,sulfur-, and phosphorous-containing xenobiotics such as therapeutic drugs, dietary compounds, pesticides, and other foreign compounds. The human FMO gene family is composed of 5 genes and multiple pseudogenes. FMO members have distinct developmental- and tissue-specific expression patterns. The expression of this FMO3 gene, the major FMO expressed in adult liver, can vary up to 20-fold between individuals. This inter-individual variation in FMO3 expression levels is likely to have significant effects on the rate at which xenobiotics are metabolised and, therefore, is of considerable interest to the pharmaceutical industry. This transmembrane protein localizes to the endoplasmic reticulum of many tissues. Alternative splicing of this gene results in multiple transcript variants encoding the same protein. Mutations in this gene cause the disorder trimethylaminuria (TMAu) which is characterized by the accumulation and excretion of unmetabolized trimethylamine and a distinctive body odor. In healthy individuals, trimethylamine is primarily converted to the non odorous trimethylamine N-oxide.[provided by RefSeq, Aug 2009]

Uniprot Description

FMO3: Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an important role in the metabolism of trimethylamine (TMA), via the production of TMA N-oxide (TMAO). Is also able to perform S-oxidation when acting on sulfide compounds. Defects in FMO3 are the cause of trimethylaminuria (TMAU); also known as fish-odor syndrome. TMAU is an inborn error of metabolism associated with an offensive body odor and caused by deficiency of FMO-mediated N-oxidation of amino- trimethylamine (TMA) derived from foodstuffs. Such individuals excrete relatively large amounts of TMA in their urine, sweat, and breath, and exhibit a fishy body odor characteristic of the malodorous free amine. Belongs to the FMO family.

Protein type: EC 1.14.13.8; EC 1.14.13.148; Xenobiotic Metabolism - drug metabolism - cytochrome P450; Oxidoreductase

Chromosomal Location of Human Ortholog: 1q24.3

Cellular Component: endoplasmic reticulum membrane; intracellular membrane-bound organelle; integral to membrane

Molecular Function: amino acid binding; FAD binding; NADP binding; flavin-containing monooxygenase activity

Biological Process: xenobiotic metabolic process; drug metabolic process

Disease: Trimethylaminuria